Insider Selling: Outset Medical (NASDAQ:OM) CFO Sells $87,299.68 in Stock

Posted by George Bondi on Jun 8th, 2026

Outset Medical, Inc. (NASDAQ:OM – Get Free Report) CFO Renee Gaeta sold 17,672 shares of the stock in a transaction dated Wednesday, June 3rd. The stock was sold at an average price of $4.94, for a total transaction of $87,299.68. Following the sale, the chief financial officer owned 113,753 shares of the company’s stock, valued at $561,939.82. This trade represents a 13.45% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Outset Medical Stock Performance

Shares of Outset Medical stock opened at $4.58 on Monday. The company has a quick ratio of 4.97, a current ratio of 6.29 and a debt-to-equity ratio of 0.87. The stock has a market capitalization of $84.91 million, a P/E ratio of -1.10 and a beta of 1.95. Outset Medical, Inc. has a 12-month low of $3.00 and a 12-month high of $21.98. The company has a 50-day simple moving average of $4.26 and a 200 day simple moving average of $4.17.

Outset Medical (NASDAQ:OM – Get Free Report) last posted its quarterly earnings data on Thursday, May 7th. The company reported ($0.83) earnings per share for the quarter, missing the consensus estimate of ($0.79) by ($0.04). The company had revenue of $27.86 million during the quarter, compared to analyst estimates of $28.90 million. Outset Medical had a negative net margin of 63.65% and a negative return on equity of 56.13%. Research analysts expect that Outset Medical, Inc. will post -3.82 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of the business. Legal & General Group Plc bought a new position in Outset Medical during the 2nd quarter worth approximately $34,000. BNP Paribas Financial Markets boosted its stake in Outset Medical by 7,013.8% during the 2nd quarter. BNP Paribas Financial Markets now owns 2,063 shares of the company’s stock worth $40,000 after acquiring an additional 2,034 shares during the last quarter. Bank of New York Mellon Corp boosted its stake in Outset Medical by 4.1% during the 1st quarter. Bank of New York Mellon Corp now owns 62,360 shares of the company’s stock worth $239,000 after acquiring an additional 2,435 shares during the last quarter. Geode Capital Management LLC boosted its stake in Outset Medical by 0.8% during the 4th quarter. Geode Capital Management LLC now owns 400,363 shares of the company’s stock worth $1,486,000 after acquiring an additional 3,104 shares during the last quarter. Finally, Barclays PLC boosted its stake in Outset Medical by 9.8% during the 4th quarter. Barclays PLC now owns 37,682 shares of the company’s stock worth $140,000 after acquiring an additional 3,356 shares during the last quarter.

Wall Street Analysts Forecast Growth

Several equities research analysts have weighed in on OM shares. TD Cowen restated a “buy” rating on shares of Outset Medical in a research report on Friday, May 8th. Wall Street Zen cut shares of Outset Medical from a “hold” rating to a “sell” rating in a research report on Saturday, April 11th. Weiss Ratings restated a “sell (e+)” rating on shares of Outset Medical in a research report on Friday, March 27th. Finally, BTIG Research lowered their price objective on shares of Outset Medical from $17.00 to $15.00 and set a “buy” rating for the company in a research report on Thursday, February 12th. Three analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus target price of $10.00.

Get Our Latest Stock Analysis on OM

About Outset Medical

(Get Free Report)

Outset Medical is a medical technology company specializing in innovations for renal care. The company’s flagship offering, the Tablo Hemodialysis System, is designed to streamline and simplify dialysis treatment across acute and outpatient settings. By integrating water purification, dialysate production, and treatment monitoring into a single device, Tablo aims to reduce the complexity and logistical burden traditionally associated with hemodialysis therapy.

Tablo’s modular design allows for rapid setup and flexible deployment in hospitals, clinics, long‐term care facilities and emergency response scenarios.